10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.65), $0.35 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $71.8 million versus the consensus estimate of $61.23 million.

Recent Highlights

• Revenue was $71.8 million for the third quarter, representing a 17% increase over the corresponding period in 2019 and a 67% increase compared to the second quarter of 2020
• Completed the acquisitions of ReadCoor and CartaNA, advancing 10x Genomics into In Situ analysis with comprehensive and foundational intellectual property, key technology advances and deep talent and expertise in the emerging field
• Completed a follow-on public offering of 4,600,000 shares of common stock resulting in approximately $482.2 million in net proceeds

"Our strong performance this quarter demonstrates our ability to execute across all facets of the business," said Serge Saxonov, Co-Founder and CEO of 10x Genomics. "We remain focused on the frontiers of scientific discovery and we will continue to invest in the vast opportunities that lie before us, both now and well into the future."

For earnings history and earnings-related data on 10x Genomics (TXG) click here.